natgillin/translations-raw huggingface dataset:
reacting compound (VII) with an organomagnesium halide; in the presence or absence of a lithium halide; in an aprotic organic solvent; at a temperature of about −50° C. to about room temperature; followed by the addition of an C1-6alkyl chloroformate or C1-6alkyl cyanoformate; to yield the corresponding ester of formula (1e). 
(le) reakcije spoja (VII) sa organomagnezijevim halogenidom; u prisustvu ili odsustvu litij halogenida; u aprotonskom organskom otapalu; na temperaturi od oko -50 *C do približno sobne temperature; praćeno dodavanjem C, salkil kloroformijata ili C, galkil cijanoformijata; da bi se dobio odgovarajući ester formule (1e).
This feature makes the sIL-6R/IL-6 complex an agonist for cell types that although they express gp130, would not inherently respond to IL-6 alone. 
Ova značajka čini kompleks sIL- 6R/IL-6 agonistom za tipove stanice koje, iako eksprimiraju gp130, ne odgovaraju inherentno na sam IL-6.
C12-200 produced a significant increase in hematocrit. 
C12-200, DOPE, CHOL i DMGPEG2K.
Therefore typically a seed coating composition of the present invention comprises a biologically effective amount of a compound of Formula 1, an N-oxide or salt thereof, and a film former or adhesive agent. 
Metoda iz Zahtjeva 23, naznačena time, što se sjeme oblaže spojem iz Zahtjeva 1 formuliranim u smjesu koja uključuje sredstvo za formiranje filma ili adhezivno sredstvo.
Ar1 is phenyl substituted with 0-3 substituents selected from the group consisting of cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and alkylSO2; 
Ar' je fenil supstituiran sa 0-3 supstituenta izabrana iz grupe koju čine cijano, halo, alkil, haloalkil, alkoksi, haloalkoksi i alkilSO»;
wherein C6-10aryl is substituted with; and the heteroaryl is optionally substituted with; one substituent selected from the group consisting of fluoro, chloro, bromo, C1-4alkyl, cyano, and trifluoromethyl. 
pri čemu je C6-10aril supstituiran sa; i heteroaril je opciono supstituiran sa; jednim supstituentom izabranim iz grupe koju čine fluoro, kloro, bromo, C1-4alkil, cijano, i trifluorometil.
represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the rings being optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group or a halogen atom; represents a benzene ring or a naphthalene ring; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a methylenedioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro, a cyano, an amino, a C1-5 monoalkylamino group or a C2-10 dialkylamino group; 
R1 znači 2-, 3- ili 4-piridinski prsten ili 2-, 4- ili 5-pirimidinski prsten, prsten izborno supstituiran s Cy4 alkilnom skupinom, Cia alkoksi skupinom ili atomom halogena; R2 predstavlja benzenski prsten ili naftalenski prsten; prstene izborno supstituiran s 1 do 4 supstituenta, koje se bira između C;.« alkilne skupine, metilendioksi skupine, atoma halogena, perhalogenirane Ci. alkilne skupine, halogenirane C,., alkilne skupine, hidroksilne skupine, Cia alkoksi skupine, nitro, cijano, amino, C;.s monoalkilamino skupine ili C2_.;9 dialkilamino skupine;
m represents an integer of 1 to 3, 
predstavlja -C(RC)(RD)-, m predstavlja cijeli broj od 1 do 3,
The viscosity typically is 10-50 Pas measured with a shear rate of 10-50 s−1, 0.4-1.5 Pas measured with a shear rate of 200-210 s−1, and 0.1-0.4 Pas measured with a shear rate of 600-610 s−1. 
viskozitet je 10-50 Pas izmjerena stopom smicanja od 10-50 s", viskozitet je 0.4-1.5 Pas izmjerena stopom smicanja od 200-210 s", i 0.1-0.4 Pas izmjerena stopom smicanja od 600-610 s".
In a further embodiment of the invention, the device prosthetic device comprises cells, such as stem cells or fat cells. 
U jednom daljnjem ostvarenju ovog izuma protetički uređaj sadržava stanice, takve kao što su hematoblasti ili masne stanice.
Thus, the method of the invention can be applied to treat or prevent withdrawal from, e.g., heroin, in a pregnant woman. 
Stoga se izum može primijeniti za liječenje ili sprječavanje ustezanja od, npr., heroina, kod trudne žene.
The method according to claim 23, wherein the composition comprises 1 to 50 wt.-% of the skin penetration enhancer. The method according to claim 26, wherein the composition comprises 5 to 10 wt.-% of the skin penetration enhancer. The method according to claim 1, wherein the composition comprises: 
Pripravak za primjenu prema zahtjevu 13, koji sadrži od 1 do 50%, poželjno od 5 do 10% promotora prodiranja kroz kožu. Pripravak za primjenu prema zahtjevu 1, koji sadrži a) 0d0,25 do 4,5% aktivne tvari za liječenje aktinske keratoze, b) od 2 do 20% keratolitički aktivne tvari,
Process according to claim 4 characterized in that the compound obtained is enantiomerically pure (S)-pirlindole hydrobromide salt. 
Proces u skladu sa patentnim zahtjevom 4 naznačen time da dobiveni spoj je enantiomerno čista (S)-pirlindol hidrobromid sol.
is a hydrogen atom, a methyl group, an ethyl group, an isopropyl group or a hexyl group, 
R' predstavlja atom vodika, metil skupinu, etil skupinu, izopropil skupinu ili heksil skupinu,
Recoil damper system according to claim 6, in which said external base (22) also includes wall sections (31) that extend towards the exterior. 
Sustav za prigušivanje trzanja u skladu s patentnim zahtjevom 6, u kojemu navedena vanjska baza (22) također ima jadan predio stijenke (31) koji se pruža prema vanjskoj strani.
Many buffers may be used in the frame of the medium of the invention, such as sodium bicarbonate buffer, Tris, BES (N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), Glycine buffer, or the like. 
Mnogi se puferi mogu koristiti u okviru medija sukladnog izumu, poput natrij bikarbonatnog pufera, Tris, BES (N,N-bis(2-hidroksietil)-2-aminoetansulfonska kiselina), glicinski pufer ili slični.
The process of claim 1 wherein the buffer is selected from the group consisting of phosphate buffer, borate buffer, acetate buffer, carbonate buffer and citrate buffer optionally wherein the buffer has a concentration between 1-50mM, 1-25mM, 1-10mM, 5-15mM, 8-12mM, or 10-50mM or around 10mM. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što pufer se bira iz skupine koju čine fosfatni pufer, boratni pufer, acetatni pufer, karbonatni pufer i citratni pufer, gdje se koncentracija pufera može kretati od 1-50 mM, 1-25 mM, 1-10 mM, 5-15 mM, 8-12 mM ili 10-50 mM ili otprilike 10 mM.
Panelized structural system for building construction 
PANELSKI KONSTRUKCIJSKI SUSTAV ZA GRADNJU GRAĐEVINA
A lipid compound according to claim 11, wherein the compound is present in the form of its S enantiomer at the carbon attached to (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy, R2, R3, and X. 
Lipidni spoj prema zahtjevu 11, pri čemu je spoj prisutan u obliku svog S enantiomera na ugljiku vezanom na (52,87,112,142,177)-ikoza-5,8,11,14,17-pentaen-1-iloksi, R>, R3 i X. Lipidni spoj prema zahtjevu 1, pri čemu je spoj: * SE Nk
a V domain of an anti-CD3 antibody comprising a VL domain comprising SEQ ID NO: 8 and/or a VH domain comprising SEQ ID NO: 7; 
V domena protutijela protiv CD3, koja sadrži VL domenu koja sadrži SEQ ID NO: 8 i/ili VH domenu koja sadrži SEQ ID NO: 7;
The composition of claim 2, wherein the composition is in the form of a solid, semi-solid, or a paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je u čvrstom, polučvrstom ili pastoznom obliku.
A method according to any one of claims 27-42, wherein a ridge of the plurality of ridges has a maximum width of less than 0.3 mm, preferably less than 0.21 mm, more preferably less than 0.15 mm. 
Postupak prema bilo kojem od patentnih zahtjeva 23-34, naznačen time da ispust (28.i) koji se sastoji od mnoštva ispusta (28.i) ima maksimalnu širinu manju od 0,3 mm, poželjno manju od 0,21 mm, a još poželjnije i manju od 0,15 mm.
The lentiviral vector packaging system of claim 10 or 11, wherein the nucleic acid encoding the non-functional integrase comprises a D64V mutation and the lentiviral vector genome comprises a deletion of the 3' LTR-proximal polypurine tract (PPT). 
Sustav pakiranja lentiviralnog vektora prema zahtjevu 10 ili 11, pri čemu nukleinska kiselina koja šifrira nefunkcionalnu integrazu sadrži D64V mutaciju i genom lentiviralnog vektora sadrži brisanje 3' LTR-proksimalnog polipurinskog trakta (PPT).
The method of claim 12, wherein said ganglioside receptor is taken from the list of GT1 b and GD1 b. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time, da je rečeni gangliozidni receptor uzet s popisa GT1 b i GD1 b.
Biodegradable polymers and compounds 
BIORAZGRADIVI POLIMERI
loading a filter housing with the mixture, wherein in the filter housing a first filter having a pore size in the range 4 um to 50 um is provided on a flat base surface and the walls of the filter housing are connected so as to seal with the flat base surface which is perforated in the manner of a sieve, 
punjenje kućišta filtra sa smjesom, pri čemu prvi filter ima veličinu pora između 4 µm i 50 µm predviđen je na ravnoj osnovnoj površini u kućištu filtera i stjenke kućišta filtera su nepropusno spojene na ravnu osnovnu površinu, koja je perforirana na način sličan situ;
The method according to claim 1, in which the L-carnitine is administered in parallel to the glucose solution, in a single dose or in divided doses, dissolved in a suitable vehicle such as, for example, distilled water, saline solution, or glucose solution. 
Upotreba u skladu s patentnim zahtjevima 1-2, naznačena time što se L-karnitin primijenjuje usporedno glukoznoj otopini, u jednoj dozi ili u podijeljenim dozama, otopljen u pogodnom vehikulumu, poput, primjerice, destilirane vode, fiziološke otopine ili glukozne otopine.
The humanized CD37-specific binding protein according to any one of the preceding claims, wherein: 
Humanizirani CD37-specifični vezni protein u skladu s patentnim zahtjevom 6, pri čemu:
This lowermost end portion is substantially uniformly wide, so as to fit inside the extended pocket 135 of the groove 122 of the key blade, and has substantially parallel, opposite side surfaces 163, 164, oriented substantially in parallel to the lateral sides 117, 118 of the keyway, and a transverse end surface 165, which is substantially flat or slightly curved and which is substantially perpendicular to the lateral sides 117, 118 of the keyway. 
navedeni podrezani dio navedenog uzdužnog profila utora, na njegovom krajnjem unutarnjem dijelu unutar navedenog dijela grebena (128), je proširen u uzdužni džep (135) koji ima suprotne bočne dijelove stjenke (132,133) 1 najdonju poprečnu krajnju stjenku (134), koja je uglavnom plosnata ili blago zakrivljena; -
disabling the watchdog circuit to cut off supply to the output optoisolator and therefore data transmission to the beacons. 
- < omogućavanje kontrolnog (watchdog) električkog kruga da isključi dobavu prema izlaznom optoizolatoru 1 na taj način prijenos podataka prema balizama.
Item 3 Method of removal of calcium from hydrocarbon feedstock, as described in item 1, wherein said mixing of step (a) of item 1, is carried out vigorously for enabling said chemical compound to chelate the calcium. 
Metoda uklanjanja kalcija 12 ugljikovodične sirovine prema patentnom zahtjevu 1 ili 2, naznačen time da je navedeno miješanje iz koraka pod (a) provedeno snažno kako bi se omogućlio da navedeni kemijski spoj kelira kalcij.
The receiver according to claim 1, wherein the sample container and the outlet comprise a bayonet joint so that the sample container is easily connected and disconnected to the receiver. 
Prijemna posuda sukladno patentnom zahtjevu 1, naznačeno time što posuda (40) za uzorak i izlazni otvor (19) sadrže bajunetni spoj tako da je posudu za uzorak lako spojiti i odspojiti na prijemnu posudu.
combining the supernatant serum with an aqueous solution of formaldehyde at a temperature of at least 37 °C for at least 28 days, 
centrifugiranja produkta iz koraka (a), kombiniranja supernatanta i/ili seruma s vodenom otopinom formaldehida,
With this arrangement the line parts can be simply hinged open without them coming apart or coming away from the chamber and after cleaning can be brought back via the hinge into the correct sealing position in which they are in contact with one another. 
Uz ovakvu izvedbu, dijelovi cijevi se mogu jednostavno otvoriti pomoću Å arki, bez da se odvajaju od komore, i nakon čišćenja se mogu vratiti pomoću šarki u ispravan položaj za brtvljenje u kojem su u međusobnom dodiru.
The antisense oligonucleotide of claim 1, wherein the antisense oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. 
Protusmisleni oligonukleotid ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 9, naznačen time što je oligonukleotid kemijski vezan na jednu ili više skupina ili konjugata koji poboljšavaju aktivnost, staničnu raspodjelu, ili stanični unos protusmislenog oligonukleotida.
The base part 5 in this embodiment comprises sealing means, e.g. 
Osnovni dio 5 u ovoj izvedbi obuhvaća sredstvo za brtvljenje, npr.
a polypeptide consisting of the sequence set forth in amino acids 19 through 134 of SEQ ID NO: 2, except for a single amino acid substitution at position 28, and a single amino acid substitution at position 44, wherein the substitution at position 28 is selected from the group consisting of W and Y, and the substitution at position 44 is T; 
polipeptid koji se sastoji od slijeda iznijetog u aminokiseline 19 do 134 u SEQ ID NO:2, osim jedne aminokiselinske zamjene na položaju koja odgovara položaju 28 u SEQ ID NO:2 i jedne aminokiselinske zamjene na položaju koja odgovara položaju 44 u SEQ ID NO:2, gdje se zamjenu na položaju 28 bira iz skupine koju čine W i Y, a zamjena na položaju 44 je T;
compaction of the mixture of step (1) on a suitable roller compactor; 
(2) sabijanje mješavine iz koraka (1) pomoću prikladnog valjka za sabijanje;
System for measuring quality of audio and video bit stream transmissions over a transmission chain, comprising: one or more measurement detectors provided along the transmission chain, said one or more measurement detectors being configured to detect the loss of bit stream packets at the one or more measurement point(s), and to determining the unique identifier for each detected lost packet; a central monitoring system receiving from said one or more measurement detectors the list of lost packet identifiers, the central monitoring system being configured to construct from a stored error free stream and on the basis of the received lost packet identifiers, simulated streams for each measurement point, and to evaluate the simulated streams for deriving a quality score for each measurement point along the transmission chain. 
Sustav za mjerenje kvalitete prijenosa audio i video struje bitova preko lanca prijenosa, naznačen time što se sastoji od: jednog ili više mjernih detektora postavljenih duž lanca prijenosa, gdje su navedeni jedan ili više mjernih detektora konfigurirani da detektiraju gubitak paketa struje bitova na jednoj ili više mjernih točaka, te da odrede jedinstveni identifikator za svaki detektirani izgubljeni paket; središnjeg sustava za praćenje koji prima iz navedenog jednog ili više mjernih detektora spisak identifikatora izgubljenih paketa, gdje je središnji sustav za praćenje konfiguriran da konstruira iz uskladištene struja bez grešaka i na osnovi primljenih identifikatora izgubljenih paketa, simulirane struje za svaku od mjernih točaka, te da procijeni simulirane struje radi dobivanje razine kvalitete za svaku od mjernih točaka duž lanca prijenosa.
Following stabilisation of the tail current amplitude, bath solution containing the vehicle for the test substance was applied to the cell. 
Nakon stabilizacije amplitude struje, otopina za kupku koja je sadržavala nosač za ispitivanu tvar je primjenjena na stanicu.
They consist of a relatively large container and a dose measuring principle that has to be operated by the patient The container bears multiple doses that are isolated individually from the bulk of powder by volumetric displacement. 
Oni se sastoje od razmjerno velikog spremnika 1 sklopa za odmjeravanje doze kojim rukuje bolesnik. Unutar spremnika nalazi se veći broj doza koje su principom volumetrijskog doziranja pojedinačno izolirane od spremišta praška.
An ophthalmic aqueous solution for treating ocular hypertension and glaucoma, comprising PGF2a, analogue and B-blocking agent as an active ingredient, wherein said ophthalmic aqueous solution contains nonionic surfactant, stabilizing agent and substantially no preservatives in a container consisting essentially of polyethylene; and the polyethylene is low density polyethylene (LDPE). 
Oftalmološka vodena otopina koja sadrži 0.0015% tež./zap. tafluprost kao aktivni sastojak, 0.075% tež./zap. polisorbat 80, 0.05% tež./zap. dinatrijev edetat, 2.25% tež./zap. glicerol, 0.2% tež./zap. natrijev dihidrogen fosfat dihidrat, vodu i sredstva za podešavanje pH kao pomoćne tvari, u spremniku koji se u bitnome sastoji od polietilena.
The compound or composition of Claim 14, wherein the second therapeutic agent is selected from ritonavir, efavirenz, didanosine, tenofovir disoproxil, nelfinavir mesilate, amprenavir, raltegravir potassium, saquinavir, lopinavir, nevirapine, emtricitabine, abacavir, lamivudine, zidovudine, maraviroc, stavudine, darunavir, fosamprenavir, vieriviroc, a pharmaccutically acceptable salt of any of the foregoing, and combinations thereof 
Spoj ili kompozicija prema zahtjevu 16, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, tenofovir dizoproksila, nelfinavir mesilata, amprenavira, kalij raltegravira, sakvinavira, lopinavira, nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicriviroca, farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih i njihovih kombinacija.
The method of any one of Claims 1 to 19, wherein said particles have an internal void volume of at least about 30% before subjecting to said external gas pressure. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 19, gdje volumen unutarnje šupljine navedenih čestica iznosi najmanje 30 % prije podvrgavanja tlaku vanjskog plina.
An aqueous pharmaceutical formulation comprising insulin glargine in a concentration of 200-650 U/mL of insulin glargine being equimolar to 200-650 IU human insulin, for use in the treatment of Type I and Type II Diabetes Mellitus in a patient. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za liječenje dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
contacting said plant with an effective concentration of glyphosate; and, growing said plant under conditions wherein the temperature is higher than ambient environmental temperature for at least two consecutive hours per day for at least four days following contact with said glyphosate, wherein said days following contact is within the growing season of the plant, wherein the vigor or yield of said plant is higher than the vigor or yield of a plant expressing a glyphosate tolerance EPSP synthase that does not have a temperature optimum higher than ambient environmental temperature, preferably wherein the temperature in step (c) is about 32°C to about 60°C. 
C) uzgoj navedene biljke pod uvjetima u kojima je temperature viša od temperature okoliša tijekom najmanje dva uzastopna sata dnevno u razdoblju od najmanje četiri dana nakon dovodenja u kontakt s glifosfatom, pri čemu su navedeni dani nakon kontakta u razdoblju rasta biljke, pri čemu je otpornost ili prinos navedene biljke viši od otpomosti ili prinosa EPSP sintaze biljke koja eksprimira otpornost na glifosfate i nema temperaturni optimum viši od temperature okoliša, poželjno kada je temperature u koraku (c) oko 32"C€ do oko 60*C.
at least one component b1), at least one component b2), at least one component b3) and at least one component b4); 
- barem jednu komponentu bl), barem jednu komponentu b2), barem jednu komponentu b3) i barem jednu komponentu b4);
A pharmaceutical composition comprising a compound which is: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski preparat koji sadrži spoj prema patentnom zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, razblaživač ili ekscipijens.
The method according to any one of claims 1-15, characterized in that the method further comprises adding a nutrient solution containing at least one dissolved nitrogen-containing, one phosphorous-containing or one potassium-containing species to the said contaminated subsurface environment prior to, during, or after the said re-introduction of the enriched consortium. 
Metoda prema bilo kojem od zahtjeva 1-15, naznačena time da ta metoda nadalje uključuje dodavanje jedne hranjive otopine koja sadrži najmanje jednu otopljenu svojtu koja sadrži dušik, jednu koja sadrži fosfor ili jednu koja sadrži kalij, u spomenuti zagađeni podzemni okoliš prije ili tijekom ili nakon spomenutog ponovnog vraćanja obogaćene mikrobne zajednice u taj okoliš.
71.5% w/w and the mixture is compressed to form tablets or filled into hard gelatin capsules containing, for example, 250 mg of the compound. 
71.5% tež a smjesa je issprešana u oblik tableta ili punjena u tvrde žclatinske kapsule koje sadrže, na primjer, 250 mg spoja.
After loading, the column was first washed with PBS pH 7.2 until no protein was detected in the fractions emerging from the column (detection at A280) and then with the low pH buffer which is recommended by the manufacturer for the elution of immunoglobulins (50 mM acetate pH 4.5 buffer, at a flow rate of 3 ml/min). 
Nakon nanošenja, kolona je najprije isprana sa PBS-om pH 7.2 sve dok više nije bilo moguće detektirati proteine u frakcijama koje su sakupljena sa kolone (detekcija na A280) 1 potom sa puferom niskog pH kojeg je preporučio proizvođač za eluaciju imunoglobulina (50 mM acetatni pufer, pH 4.5, pri brzini protoka od 3 ml/min).
Panel according to the preceding claims, characterized in that the cross-section of the longitudinal cavities is such as to maintain a structure with inclined theoretical webs directed in all cases towards the inside and converging towards the centre of the said cavity. 
Ploča (1000) prema prethodnim zahtjevima, naznačena time, da je poprečni presjek od uzdužnih šupljina takav, da može održavati konstrukciju s nagnutim teoretskim pločicama koje su usmjerene u svakom slučaju prema unutra i konvergiraju u smjeru prema središtu spomenute šupljine.
A process for preparing a precipitated calcium carbonate product comprising the steps of: 
PATENTNI ZAHTJEVI Postupak za dobivanje proizvoda taložnog kalcijevog karbonata koji sadrži korake:
The second member is preferably pivotably connected to the first member. 
Ventilatorski sustav prema zahtjevu 2. gdje je drugi član (300) pivotalno spojen na prvi član (304).
wherein, the range of the weight percentage ratio C1 = (MgO+SrO)/CaO is 0.8-1, and the range of the weight percentage ratio C2 = CaO/MgO is greater than 1 and less than 1.3. 
gdje raspon omjera masenog postotka C1 = (MgO+SrO) / CaO iznosi 0,8-1, a raspon omjera masenog postotka C2 = Cao / MgO iznosi više od 1 i manje od 1,3.
The gut hormone secretion in the present invention is stimulated in L-cells present in the colon, normally in response to the presence of nutrients in the gut. 
Smjesa prema patentnom zahtjevu 1, naznačena time, što je smjesa formulirana u sistemu za dostavu lijeka koji cilja debelo crijevo.